Company profile
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BBO-8520 | phase1 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06917079 | phase1 | recruiting | 2025-03-31 | 2027-08-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
| NCT06625775 | phase1 | recruiting | 2024-10-29 | 2028-11-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors |
| NCT06343402 | phase1 | recruiting | 2024-05-22 | 2031-04-01 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer |
FDA applications (0)
No records yet.